Diagnostic Modalities and Nodal Staging in High-Risk Cutaneous Squamous Cell Carcinoma
JAMA Dermatology · 01.06.2026 · 162 (6) · 561
DOI: 10.1001/jamadermatol.2026.0803 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift JAMA Dermatology, erschienen am 01.06.2026. Verfasst von Carla Ferrándiz-Pulido und 28 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Hospital Universitari Vall d'Hebron, Barcelona, Spain. Hauptthemen laut MEDLINE: Cutaneous Squamous Cell Carcinoma, Skin Neoplasms, Lymphatic Metastasis, Lymph Nodes. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance Early detection of nodal metastases in high-risk cutaneous squamous cell carcinoma (cSCC) is crucial, yet the optimal baseline staging approach remains uncertain.
Objective
To compare the diagnostic performance of physical examination, ultrasonography, and contrast-enhanced computed tomography (CT) in detecting nodal metastases at baseline staging of high-risk cSCC, both overall and stratified by patients’ immune status. Design, Setting, and Participants This was a prospective, multicenter, paired diagnostic study conducted from January 2022 to April 2025 across 13 tertiary dermato-oncology centers in Spain. The study included patients with histologically confirmed high-risk cSCC (stage T2b/T3 or T2a with additional high-risk features). Data were analyzed from July to September 2025. Main Outcomes and Measures Sensitivity, specificity, predictive values, and area under the receiver operating characteristic curve (AUROC) of each diagnostic modality, benchmarked against histology or short-term clinical follow-up as reference standard.
Results
The analysis included 155 patients (median [IQR] age, 80.3 [74.4-85.5] years; 34 [21.9%] female and 121 [78.1%] male; 64 [41.3%] immunosuppressed), of whom 12 patients (7.7%; 95% CI, 4.3%-13.4%) developed nodal metastases within 3 months after surgery. Ultrasonography results showed the highest overall sensitivity (63.6%; 95% CI, 30.8%-89.1%), followed by CT (54.5%; 95% CI, 23.4%-83.3%) and physical examination (8.3%; 95% CI, 0.2%-38.5%). Specificities were 95.6% (95% CI, 90.6%-98.4%), 95.0% (95% CI, 90.0%-98.0%), and 99.3% (95% CI, 96.2%-100%), respectively. Ultrasonography and CT demonstrated almost perfect agreement (κ = 0.87; 95% CI, 0.72-1.00), whereas concordance with physical examination was poor. Subgroup analysis by immune status revealed marked disparities in diagnostic performance. In patients with immunocompetence, both ultrasonography and CT achieved 100% sensitivity (95% CI, 54.1%-100% and 47.8%-100%, respectively) and excellent AUROC (0.98; 95% CI, 0.96-1.00 for both). In contrast, sensitivity declined markedly among patients who were immunosuppressed (20.0% [95% CI, 0.5%-71.6%] for ultrasonography and 16.7% [95% CI, 0.4%-64.1%] for CT; AUROCs, 0.57 ([95% CI, 0.37-0.77] and 0.55 [95% CI, 0.38-0.72], respectively), with metastases often emerging abruptly during follow-up despite negative baseline staging. Conclusions and Relevance This diagnostic study found that ultrasonography and CT significantly outperformed physical examination for detecting baseline nodal metastases in high-risk cSCC and can be used interchangeably depending on clinical context and resource availability. However, their poor performance in patients with immunosuppression reveals a need for tailored recommendations in future clinical practice guidelines and emphasizes the importance of close clinical follow-up in this subgroup.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Dermatology, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
- Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain.
- Department of Radiology, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
- Department of Dermatology, Clínica Universidad de Navarra, Pamplona, Spain.
- Department of Dermatology, Hospital Universitari Arnau de Vilanova, Lleida, Spain.
- Department of Radiology, Hospital Universitari Santa Maria de Lleida, Lleida, Spain.
Zitieren
APA
Ferrándiz-Pulido, C., Gómez-Tomás, Á., Siurana, S., Tortajada, C., Salido-Vallejo, R., Aguayo-Ortiz, R. S., Ribes Amorós, I., Turrión-Merino, L., Brea Álvarez, B., Pérez González, Í., Martí-Marti, I., Medrano-Martorell, S., Podlipnik, S., Mollet, J., Masferrer, E., Lopez-Castillo, D., Yébenes, M., Corbacho-Monné, M., Leal, L., …, & Toll, A. (2026). Diagnostic Modalities and Nodal Staging in High-Risk Cutaneous Squamous Cell Carcinoma. JAMA Dermatology, 162(6), 561. https://doi.org/10.1001/jamadermatol.2026.0803
Vancouver
Ferrándiz-Pulido C, Gómez-Tomás Á, Siurana S, Tortajada C, Salido-Vallejo R, Aguayo-Ortiz RS, et al. Diagnostic Modalities and Nodal Staging in High-Risk Cutaneous Squamous Cell Carcinoma. JAMA Dermatology. 2026;162(6):561. doi:10.1001/jamadermatol.2026.0803
BibTeX
@article{FerrndizPulido2026,
author = {Ferrándiz-Pulido, Carla and Gómez-Tomás, Álvaro and Siurana, Sahyly and Tortajada, Carles and Salido-Vallejo, Rafael and Aguayo-Ortiz, Rafael S and Ribes Amorós, Iolanda and Turrión-Merino, Lucía and Brea Álvarez, Beatriz and Pérez González, Íñigo and Martí-Marti, Ignasi and Medrano-Martorell, Santiago and Podlipnik, Sebastian and Mollet, Jordi and Masferrer, Emili and Lopez-Castillo, Daniel and Yébenes, Mireia and Corbacho-Monné, Marc and Leal, Lorena and Solano-López, Alberto and Ruiz-Salas, Verónica and Granell-Moreno, Esther and Alfonso, Sheila and Mendoza, Maria-Dolores and Martínez-Domenech, Álvaro and Juárez-Dobjanschi, Cecilia and González, Elia Samaniego and Díaz, Paula and Toll, Agustí},
title = {Diagnostic Modalities and Nodal Staging in High-Risk Cutaneous Squamous Cell Carcinoma},
journal = {JAMA Dermatology},
year = {2026},
volume = {162},
number = {6},
pages = {561},
doi = {10.1001/jamadermatol.2026.0803}
}
EUVIMED